ATXI
Avenue Therapeutics, Inc.NASDAQHealthcare$0.35+0.00%ClosedMarket Cap: $1.1M
As of 2026-04-07
Valuation
P/E (TTM)
—
PEG
—
P/B
0.50
P/S
0.66
EV/EBITDA
0.59
DCF Value
$20.40
FCF Yield
-198.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
-219.6%
Net Margin
-207.2%
ROE
-89.8%
ROA
-99.2%
ROIC
-168.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | -Infinity% | $-751.0K | $-709.0K | $-0.21 | — |
| FY 2025 | $1.4M | 100.0% | $-3.1M | $-2.9M | $-0.93 | — |
| Q3 2025 | $0.00 | NaN% | $-724.0K | $-683.0K | $-0.21 | — |
| Q2 2025 | $1.4M | 100.0% | $297.0K | $335.0K | $0.11 | — |
| Q1 2025 | $0.00 | NaN% | $-1.9M | $-1.9M | $-0.62 | — |
| Q4 2024 | $0.00 | NaN% | $-1.6M | $-1.5M | $4.54 | — |
| FY 2024 | $0.00 | NaN% | $-11.3M | $-11.7M | $-0.90 | — |
| Q3 2024 | $0.00 | NaN% | $-3.2M | $-3.1M | $-1.92 | — |
| Q2 2024 | $0.00 | NaN% | $-2.8M | $-7.2M | $-6.43 | — |
| Q1 2024 | $0.00 | NaN% | $-3.7M | $-4.3M | $-7.72 | — |
| Q4 2023 | $0.00 | NaN% | $-2.1M | $640.0K | $0.03 | — |
| FY 2023 | $0.00 | NaN% | $-14.5M | $-10.4M | $-73.48 | — |